Compare Incyte Corporation (INCY) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Incyte Corporation trades at $113.13 (market cap $22.85B), while YieldMax NVDA Option Income Strategy ETF trades at $12.58 (market cap $1.45B). The key difference: Incyte Corporation is far larger — about 15.8× YieldMax NVDA Option Income Strategy ETF's market cap, and Incyte Corporation is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and YieldMax NVDA Option Income Strategy ETF for 43 Days on average.
| INCY | NVDY | |
|---|---|---|
Market Cap | $22.85B | $1.45B |
Volume | 1,927,029 | 1,943,739 |
Sector | Health | Income / Options Overlay |
52-Week High | $129.93 | $17.21 |
52-Week Low | $83.80 | $11.58 |
Typical Hold Time | 33 Days | 43 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
NVDY trades at $12.565, down 3.42% today amid bearish technical signals. The ETF shows consistent weekly dividend distributions but faces structural limitations on upside participation. Recent analyst coverage highlights declining volatility in underlying NVDA shares, reducing option income potential while NAV erosion remains a concern.
Outlook remains cautious as the fund's high distribution yield comes at the cost of long-term capital appreciation. Key risks include capped upside participation and dependency on NVDA volatility. Investors seeking pure NVDA exposure may find direct ownership more attractive for growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
